Ovarian Serous Adenocarcinoma

Independent validation in TCGA supports the potential clinical relevance of this mutational signature. These findings warrant further validation in larger prospective cohorts and functional studies to clarify their role as biomarkers of aggressive disease and therapeutic vulnerability.

This two-sample MR study provides preliminary genetic evidence that inflammatory cytokines contribute to SOC risk, with lipid metabolism partially mediating IL-8 effects. These findings highlight the interplay between inflammation and metabolism in SOC pathogenesis and suggest potential biomarkers and therapeutic targets. Due to limited sample sizes and European-only ancestry datasets, these findings require validation in larger, multi-ancestry cohorts.

These data confirm that the use of olaparib as long-term maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer is tolerable. Adverse events occurred early, were manageable, and few occurred with late onset.

P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Feb 2026 --> May 2027

In this study, we performed integrative transcriptomic profiling of patient-derived TCGA ovarian tumor samples and carboplatin-resistant A2780 (CBDCA-R-A2780) cells to identify lncRNAs whose dysregulation overlaps between a cell-line resistance model and patient tumors...Because A2780 has been discussed as an endometrioid-like/non-serous ovarian cancer model, mechanistic inferences primarily apply to this in vitro context, while TCGA analyses provide associative support rather than mechanistic validation. Collectively, these findings highlight MNX1-AS1 as a candidate regulator associated with transcriptional reprogramming in OC and a promising prognostic biomarker warranting further functional testing.

In addition, the combination therapy induces ferroptosis by inhibiting the Nrf2/SLC7A11/GPX4 axis, thereby exerting cytotoxic effects. Our results uncover a novel mechanism by which inhibiting DYRK1B enhances the anti-HGSOC efficacy of Niraparib and may offer a promising treatment strategy to improve the maintenance therapy in both HRD and HRP ovarian cancer patients.

P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027

P1, N=495, Recruiting, Eli Lilly and Company | N=223 --> 495

Avutometinib plus defactinib represents a promising targeted therapeutic strategy for recurrent LGSOC, particularly in patients with KRAS-mutant tumors. If confirmed in phase III trials, this combination may establish a molecularly informed disease-specific treatment paradigm with the potential for more durable disease control than existing therapies.

STAT1 and IL-7 are consistently differentially expressed between HGSOC and LGSOC and may serve as ancillary diagnostic biomarkers in histologically ambiguous cases. However, their clinical utility-particularly in multi-gene combinations-requires prospective validation.

P=N/A, N=200, Not yet recruiting, University of Ottawa | Trial completion date: Feb 2027 --> May 2028 | Trial primary completion date: Feb 2027 --> May 2028

This study shows that ascites can be a suitable specimen for BRCA1/2 NGS testing, and provides a minimally invasive option for disease diagnosis and the early detection of key molecular biomarkers essential for the clinical management of women with HGSOC.